文献速递核素与放射性配体治疗肿瘤 PET/CT

225Ac-PSMA-617用于化疗初治晚期前列腺癌患者的初步研究

225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2018-09-19

该初步研究纳入17例化疗初治的晚期转移性前列腺癌患者,接受225Ac-PSMA-617放射性配体治疗,初始活度8 MBq、每2个月一次,反应良好者递减至7、6或4 MBq。16/17例显示良好抗肿瘤活性,14/17例PSA下降≥90%,其中7例PSA不可测。作者认为该方案疗效显著且递减活度可降低唾液腺毒性,需进一步探索。

要点

  • 17例化疗初治晚期前列腺癌患者接受225Ac-PSMA-617治疗,14/17例PSA下降≥90%。
  • 15/17例68Ga-PSMA-PET/CT病灶摄取下降>50%,其中11例全部转移灶完全消退。
  • 全部患者出现1/2级口干,1例3级贫血、1例4级肾毒性。

核心结论

  • 225Ac-PSMA-617放射性配体治疗使化疗初治晚期转移性前列腺癌患者中82%出现血清PSA下降≥90%,包括41%患者PSA不可测且治疗后12个月仍处于缓解。
  • 本研究报道的显著疗效可通过后续治疗周期递减给药活度来降低唾液腺毒性。
  • 作者认为这需要进一步探索,以指导临床实践和临床试验设计。

研究设计与样本

  • 初步研究,纳入17例晚期前列腺癌患者,接受225Ac-PSMA-617治疗,间隔2个月,初始活度8 MBq,反应良好者递减至7 MBq、6 MBq或4 MBq。
  • 1例患者在第三周期活度递增至13 MBq;14例完成3个治疗周期,3例因反应良好在2个周期后停止治疗;17例中6例在第三周期后接受额外治疗。
  • 每4周检测PSA评估PSA反应,每后续治疗周期前用68Ga-PSMA-PET/CT评估功能反应,系列全血细胞计数、肾功能和肝功能检查评估治疗相关副作用。

主要发现

  • 16/17例经血清PSA和68Ga-PSMA-PET/CT评估显示良好抗肿瘤活性。
  • 14/17例治疗后PSA下降≥90%,其中7例在2个周期(2/7)或3个周期(5/7)后血清PSA不可测。
  • 15/17例68Ga-PSMA-PET/CT示病灶示踪剂摄取下降>50%,包括11例全部转移灶完全消退(PET阴性且骨病灶CT上硬化稳定或淋巴结转移消退)。
  • 全部患者出现1/2级口干,无严重到导致停止治疗者;1例广泛骨髓转移伴背景贫血患者出现3级贫血,另1例孤立肾且治疗前3级肾功能衰竭患者出现4级肾毒性。
  • 该组患者骨痛显著缓解,因递减活度唾液腺毒性降低。

关键数值与推荐

  • PSA下降≥90%:14/17例(82%)。
  • PSA不可测:7/17例(41%),其中2/7例在2个周期后、5/7例在3个周期后。
  • 68Ga-PSMA-PET/CT病灶摄取下降>50%:15/17例;全部转移灶完全消退:11例。
  • 口干:全部患者为1/2级;3级贫血1例;4级肾毒性1例。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A remarkable therapeutic efficacy has been demonstrated with 225Ac-prostate-specific membrane antigen (PSMA)-617 in heavily pre-treated metastatic castration-resistant prostate cancer (mCRPC) patients. We report our experience with 225Ac-PSMA-617 therapy in chemotherapy-naïve patients with advanced metastatic prostate carcinoma. METHODS: Seventeen patients with advanced prostate cancer were selected for treatment with 225Ac-PSMA-617 in 2-month intervals, with initial activity of 8 MBq, then de-escalation to 7 MBq, 6 MBq or 4 MBq in cases of good response. In one patient, activity was escalated to 13 MBq in the third cycle. Fourteen patients had three treatment cycles administered, while in three patients treatment was discontinued after two cycles due to good response. Six out of 17 patients received additional treatments after the third cycle. Prostate-specific antigen (PSA) was measured every 4 weeks for PSA response assessment. 68Ga-PSMA-PET/CT was used for functional response assessment before each subsequent treatment cycle. Serial full blood count, renal function test, and liver function were obtained to determine treatment-related side effects. RESULTS: Good antitumor activity assessed by serum PSA level and 68Ga-PSMA-PET/CT was seen in 16/17 patients. In 14/17 patients, PSA decline ≥90% was seen after treatment, including seven patients with undetectable serum PSA following two (2/7) or three cycles (5/7) cycles of 225Ac-PSMA-617. Fifteen of 17 patients had a > 50% decline in lesions avidity for tracer on 68Ga-PSMA-PET/CT including 11 patients with complete resolution (PET-negative and either stable sclerosis on CT for bone or resolution of lymph node metastases) of all metastatic lesions. Grade 1/2 xerostomia was seen in all patients, and none was severe enough to lead to discontinuation of treatment. One patient had with extensive bone marrow metastases and a background anemia developed a grade 3 anemia while another patient with solitary kidney and pre-treatment grade 3 renal failure developed grade 4 renal toxicity following treatment. The group presented with significant palliation of bone pain and reduced toxicity to salivary glands due to de-escalation. CONCLUSIONS: 225Ac-PSMA-617 RLT of chemotherapy-naïve patients with advanced metastatic prostate carcinoma led to a ≥ 90% decline in serum PSA in 82% of patients including 41% of patients with undetectable serum PSA who remained in remission 12 months after therapy. The remarkable therapeutic efficacy reported in this study could be achieved with reduced toxicity to salivary glands due to de-escalation of administered activities in subsequent treatment cycles. This necessitates further exploration for informing clinical practice and clinical trial design.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Sathekge M, Bruchertseifer F, Knoesen O, et al. 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study. Eur J Nucl Med Mol Imaging. 2018. PMID: 30232539. doi:10.1007/s00259-018-4167-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。